Genetic Predisposition to Hematological Malignancies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 20 December 2026 | Viewed by 662
Editor
Interests: acute leukemias; oncogenic fusions and chromosomal translocations; epigenetic regulation; cancer genomics and transcriptomics; precision medicine in hematology
Special Issue Information
Dear Colleagues,
Genetic predisposition critically influences the risk and clinical course of hematological malignancies. A growing body of evidence highlights the contribution of germline variants to leukemia susceptibility, often manifesting through family history, congenital anomalies, unexplained cytopenias, or unusual responses to therapy. These variants may arise de novo but in many cases are inherited and passed down over generations. Most predisposition syndromes follow an autosomal dominant inheritance with variable penetrance, while autosomal recessive and X-linked conditions, such as bone marrow failure and immune deficiency syndromes, also confer a substantial risk of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Unlike sporadic cases, germline predisposition affects all cells of the body and therefore has far-reaching clinical and familial implications. This Special Issue will bring together recent advances in the field, from molecular mechanisms to diagnostic strategies, and explore the implications for genetic counseling, patient care, and precision medicine.
Dr. Danika Di Giacomo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- leukemia predisposition
- germline variants
- inherited syndromes
- myelodysplastic syndrome (MDS)
- acute myeloid leukemia (AML)
- precision medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
